The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) continues to fragment as newer entrants such as Novartis’s Kesimpta, Bristol Myers Squibb’s Zeposia, and Janssen’s Ponvory propel ongoing shifts and intensify competition in the saturated relapsing MS market. Meanwhile, many developers have renewed focus on developing treatments for the underserved progressive MS population, including Sanofi and Roche’s BTK inhibitors and several other novel products. Meanwhile, the U.S. launch of generics competition for Tecfidera in 2020 and the anticipated entry of generic orals in Europe in the coming years will constrain uptake of follow-on compounds and exert new pressures on the market overall as reimbursement authorities struggle to rein in healthcare costs. Understanding these market forces will be key to the success of current and future players in this evolving market. inhibitors and several other novel products. Critically, the recent and near-term anticipated entry of generic orals in the market will constrain uptake of follow-on compounds and exert new pressures on the market overall as reimbursement authorities struggle to rein in healthcare costs. Understanding these market forces will be key to the success of current and future players in this evolving market.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 28 country-specific interviews with thought-leading neurologists, supported by survey data collected for this content and other Clarivate research.
Epidemiology: Diagnosed prevalence of MS by country, segmented by CIS, RR-MS, SP-MS, and PP-MS; drug-treated cases.
Emerging therapies: Phase II: 10 drugs; Phase III / preregistration: 7 drugs.
Key companies: AB Science, Banner Life Sciences, Biogen, Bristol Myers Squibb, Janssen, Merck KGaA / EMD Serono, MediciNova, Mylan, Mapi Pharma, Novartis, Roche / Genentech, Sanofi Genzyme, Teva, TG Therapeutics.
Market forecast features: Patient-based market forecast extending through 2030, segmented by brands and generics / biosimilars.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.